eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.
january 2016 (24)
.
official guidelines say no one should wait more than 62 days to get cancer care after an urgent referral by their gp.
.